Currently out of the existing stock ratings of Gary Nachman, 222 are a BUY (72.08%), 85 are a HOLD (27.6%), 1 are a SELL (0.32%).

Gary Nachman

Work Performance Price Targets & Ratings Chart

Analyst Gary Nachman, currently employed at CANACCORD, carries an average stock price target met ratio of 49.57% that have a potential upside of 71.28% achieved within 417 days. Previously, Gary Nachman worked at RAYMOND JAMES.

Gary Nachman’s has documented 608 price targets and ratings displayed on 44 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ETON, Eton Pharmaceuticals at 05-Nov-2026.

Wall Street Analyst Gary Nachman

Analyst best performing recommendations are on NMTR (9 METERS BIOPHARMA).
The best stock recommendation documented was for NMTR (9 METERS BIOPHARMA) at 6/22/2022. The price target of $240 was fulfilled within 5 days with a profit of $73.85 (44.45%) receiving and performance score of 88.9.

Average potential price target upside

of $54.74 (40.08%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $41.46 (595.63%) on SRRK (SCHOLAR ROCK HOLDING CORP).
of $39.06 (27.99%) on ABBV (ABBVIE).

AMPH Amphastar P APTX Aptinyx AQST Aquestive Therapeutics BHC Bausch Health Companies ENDP Endo International PLC FLXN Flexion Therapeutics HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC LCI Lannett Company MNK Mallinckrodt plc MYL Viatris NEOS Neos Therapeutics OPTN OptiNose PCRX Pacira Pharmaceuticals SAGE Sage Therapeutic ABBV AbbVie PHAT Phathom Pharmaceuticals RIGL Rigel Pharmaceuticals PYPD PolyPid VTRS Viatris SRRK Scholar Rock Holding Corp TEVA Teva Pharma Industries Ltd ADR MORF Morphic ALNY Alnylam Pharmaceuticals ABCL Abcellera Biologics EVLO Evelo Biosciences SDGR Schrodinger SLGL Sol Gel Technologies Ltd AMGN Amgen IONS Ionis Pharmaceuticals TRVI Trevi Therapeutics VERU Veru BLCO Bausch + Lomb Corp AP Ampco-Pittsburgh INMB INmune Bio LENZ LENZ Therapeutics SA Seabridge Gold ACHV Achieve Life Sciences ADMA ADMA Biologics AMRX Amneal Pharmaceuticals ANIP ANI Pharmaceuticals ETON Eton Pharmaceuticals NMTR 9 Meters Biopharma SCPH Scpharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Benjamin Burnett (WELLS FARGO)

Hold Since 13-May-2026

$25

$-3.49 (-12.25%)

$20

Please subscribe to see extended stock data

Glen Santangelo (BARCLAYS)

Hold Since 08-Apr-2026

$23

$-5.49 (-19.27%)

$20

2 months 25 days ago
(18-Aug-2026)

5/8 (62.5%)

$1.66 (7.78%)

Please subscribe to see extended stock data

David Amsellem (PIPER SANDLER)

Hold Since 21-Mar-2025

$20

$-8.49 (-29.80%)

$21

3 months 5 days ago
(07-Aug-2026)

14/21 (66.67%)

$-0.78 (-3.75%)

246

Please subscribe to see extended stock data

Jason Gerberry (BAML)

Hold Since 17-Nov-2023

$20

$-8.49 (-29.80%)

$32

4 months 14 days ago
(29-Jun-2026)

2/3 (66.67%)

$-0.71 (-3.43%)

Please subscribe to see extended stock data

Cerena Chen (WELLS FARGO)

Buy Since 22-Nov-2024

$19

$-2.78 (-12.76%)

$35

5 months 29 days ago
(14-May-2026)

1/3 (33.33%)

$1.7 (9.83%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Gary Nachman most bullish on?

Potential upside of $55.24 has been obtained for JAZZ (JAZZ PHARMACEUTICALS PLC)

Which stock is Gary Nachman most reserved on?

Potential downside of $0.18 has been obtained for SDGR (SCHRODINGER)

What Year was the first public recommendation made by Gary Nachman?

On 2013